Clinical Trial Update: De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating de-escalation of neoadjuvant therapy with paclitaxel plus trastuzumab and pertuzumab (HP) in early HER2-positive breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• PACLITAXEL (PACLITAXEL)
• Perjeta (pertuzumab)

Snippet

Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING